Bing

SEARCH HISTORY

On Wednesday, small cap biotech stock Incyte Corporation (NASDAQ: INCY) soared after announcing positive top-line results of the Phase II trial of ruxolitinib for patients with recurrent or treatment refractory metastatic pancreatic cancer, meaning it ...
Smallcap Network · ByJohn Udovich · 8/22/2013
Like the incy wincy spider, US markets are going to have another go ... That was yesterday, however, and although European markets are mostly a little lower and Chinese stocks took another bath overnight, US …
Proactiveinvestors · 8/26/2015
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Incyte Corporation (INCY - Analyst Report). This Medical-Biomedical stock has actually seen estimates rise over the past month for the current ...
ZACKS · 8/11/2015
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Incyte Corporation (INCY). This Medical-Biomedical stock has actually seen estimates rise over the past month for the current fiscal year by about ...
Yahoo Finance · 8/11/2015
Why Incyte Corporation (INCY) Might Be a Diamond in the Rough - Tale of the Tape (Zacks) In a report published Thursday, Barclays analyst Geoff Meacham initiated coverage of Incyte Corporation (NASDAQ: INCY) with an Overweight rating and a price …
Benzinga · ByMonica Gerson · 8/13/2015
Boston, MA 10/04/2013 (wallstreetpr) – Incyte Corporation (NASDAQ:INCY) has announced the results of a 28-day, PhaseII, placebo-controlled clinical-trial that was conducted on 50 patients suffering from chronic plaque psoriasis, for INCB39110, the ...
wallstreetpr.com · 10/4/2013
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 17, Incyte Corporation's Director, Wendy L Dixon, invested $100,496.53 into 7,500 shares of INCY ...
Yahoo News · 11/22/2011
Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today. Incyte Pharmaceuticals (NASDAQ: INCY ) has been on a tear since its only approved drug, Jakafi, won FDA approval in November 2011 for ...
The Motley Fool · 3/28/2014
In a research note from SunTrust Robinson Humphrey, analyst Salveen Richter has maintained that mergers and acquisitions will be a huge driving force to a continued run in the biotech industry ... Corp. (NASDAQ: INCY) is another top stock that could ...
24/7 Wall ST · 3/6/2015
Agenus Inc (NASDAQ:AGEN) stock surged 28.71% on Friday, following news that the biotechnology company has entered into a partnership with Incyte Corporation (NASDAQ:INCY). The partnership will focus on “novel immuno-therapeutics using Agenus ...
bidnessetc.com · 1/11/2015